Literature DB >> 3679093

Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis.

J C Homberg1, N Abuaf, O Bernard, S Islam, F Alvarez, S H Khalil, R Poupon, F Darnis, V G Lévy, P Grippon.   

Abstract

Sixty-five patients with histologically proven chronic active hepatitis of unknown cause but associated with the antiliver/kidney microsome antibody type 1, confirmed by immunofluorescence and immunoprecipitation, were selected as forming a special entity. This disease was found to be rare with a prevalence of 5/1,000,000. The female to male ratio was 8:1. The condition occurred at all ages but was most common between the ages of 2 and 14 years. In 22 of the 65 cases, the hepatitis was associated with an autoimmune disease, most commonly insulin-dependent diabetes, autoimmune thyroid disease and vitiligo. The same autoimmune diseases were present in first-degree relatives from seven families. In 36 cases, the onset of disease resembled acute viral hepatitis. Serum biochemical tests showed marked elevation in aminotransaminases and hypergammaglobulinemia. Paradoxically, serum and salivary IgA levels were often normal or low. Histologic findings were multifocal hepatic necrosis with bridging in the acute stage, and aggressive hepatitis with mononuclear cell infiltration or macronodular cirrhosis in the late stages. Serologically, apart from the presence of antiliver/kidney microsome antibody type 1, the disease was characterized by the absence of antiactin, antimitochondria and antinucleus antibodies; however, organ-specific autoantibodies were often present. The clinical course was usually severe: six patients in the acute stage presented with fulminant hepatitis, and all, except two, other patients progressed to cirrhosis. Prolonged treatment with corticosteroids and immunosuppressants was usually effective in rendering the cirrhosis inactive. The cumulative survival rate was 51% at 14 years. We propose to call this entity "anti-LKM1 chronic active hepatitis" or "autoimmune hepatitis type II" to differentiate it from classical "lupoid hepatitis" or autoimmune hepatitis type I.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3679093     DOI: 10.1002/hep.1840070626

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  91 in total

Review 1.  Autoimmune hepatitis.

Authors:  E A Roberts
Journal:  Indian J Pediatr       Date:  1995 Sep-Oct       Impact factor: 1.967

Review 2.  Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update.

Authors:  E Boitier; P Beaune
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 3.  Autoimmunity in liver diseases.

Authors:  C P Strassburg; P Obermayer-Straub; M P Manns
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 4.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

5.  Detection of liver kidney microsomal type 1 antibody using molecularly based immunoassays.

Authors:  N Kerkar; Y Ma; E T Davies; P Cheeseman; G Mieli-Vergani; D Vergani
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

6.  Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis.

Authors:  M Costa; J L Rodríguez-Sánchez; A J Czaja; C Gelpí
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 7.  Genetic bases of autoimmune hepatitis.

Authors:  Albert J Czaja; Derek G Doherty; Peter T Donaldson
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

Review 8.  Immunological abnormalities and hepatotropic viral infections.

Authors:  I G McFarlane
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

Review 9.  Autoantibodies as prognostic markers in autoimmune liver disease.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-05-13       Impact factor: 3.199

10.  Cytochrome P450IID6 recognized by LKM1 antibody is not exposed on the surface of hepatocytes.

Authors:  A M Yamamoto; C Mura; C De Lemos-Chiarandini; R Krishnamoorthy; F Alvarez
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.